Targeted alpha therapy of glioblastoma multiforme: clinical experience with 213Bi- and 225Ac-Substance P

Glioblastoma multiforme (GBM), the most common primary brain tumor in adults, has a very poor prognosis with a median overall survival of 14.6 months despite of aggressive therapy. Targeted alpha therapy (TAT) with the short range, high LET alpha emitters 213Bi and 225Ac offers the potential for selective irradiation of tumors and minimizing damage to adjacent regions of the brain. The low-molecular weight peptide carrier substance P is targeting NK 1 receptors, which are consistently over-expressed on GBM cells. We report our clinical experience with 213Bi-DOTA-Substance P (213Bi-SP) and 225Ac-DOTAGA-Substance P (225Ac-SP) in patients with recurrent GBM.

KROLICKI Leszek;  BRUCHERTSEIFER Frank;  KUNIKOWSKA Jolanta;  KOZIARA H;  KROLICKI B;  JAKUCINSKI M;  PAWLAK Dariusz;  APOSTOLIDIS Christos;  ROLA R;  MERLO A.;  MORGENSTERN Alfred; 

2017-08-01

European Commission - Joint Research Centre

JRC106153

http://nucmed.w3.kanazawa-u.ac.jp/symposium/tat10/,    https://publications.jrc.ec.europa.eu/repository/handle/JRC106153,